In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor

J. J. Casal-Dominguez, M. Clark, J. R. Traynor, S. M. Husbands, Sarah J. Bailey

Research output: Contribution to journalArticle

8 Citations (Scopus)
116 Downloads (Pure)

Abstract

Accumulating evidence supports a role for κ−opioid receptor antagonists in the treatment of mood disorders. Standard κ-antagonists have an unusual pharmacodynamic action, with a single injection blocking receptor signaling for several weeks. Here, we have characterized the κ-selective properties of two ligands, 5’-(2-aminomethyl) naltrindole (5’-AMN) and N-((Naltrindol-5-yl) methyl) pentanimidamide (5’-MABN), to identify whether modifications of the naltrindole side chain produces short-acting κ-antagonists. Opioid receptor binding affinity and activity were assessed using [3H]-diprenorphine binding, guanosine-5’-O-(3-[35S]-thio) triphosphate ([35S]-GTPγS) binding and isolated guinea-pig ileum. Pharmacodynamic profiles of 5’-AMN and 5’-MABN (1–10 mg/kg) were investigated using the tail-withdrawal assay and diuresis. Efficacy was also determined in depression- and anxiety-related behavioral paradigms in CD-1 mice. Both 5’-AMN and 5’-MABN had high affinity for κ−receptors (Ki 1.36±0.98 and 0.27±0.08, respectively) and were revealed as potent κ-antagonists (pA2 7.43 and 8.18, respectively) and μ-receptor antagonists (pA2 7.62 and 7.85, respectively) in the ileum. Contrary to our hypothesis, in vivo, 5’-AMN and 5’-MABN displayed long-lasting antagonist effects in mice, reducing the antinociceptive actions of U50,488 (10 mg/kg) at 28 and 21 days post-injection, respectively. Interestingly, while 5’-AMN and 5’-MABN were not κ-selective, both compounds did show significant antidepressant- and anxiolytic-like effects at 7–14 days post-injection in mice.
Original languageEnglish
Pages (from-to)192-202
Number of pages11
JournalJournal of Psychopharmacology
Volume27
Issue number2
Early online date31 Oct 2012
DOIs
Publication statusPublished - Feb 2013

Fingerprint

naltrindole
kappa Opioid Receptor
Ligands
Ileum
Injections
Diprenorphine
Guanosine 5'-O-(3-Thiotriphosphate)
Narcotic Antagonists
mu Opioid Receptor
Diuresis
Anti-Anxiety Agents
Opioid Receptors
Mood Disorders
Antidepressive Agents
In Vitro Techniques
Tail
Guinea Pigs
Anxiety

Cite this

In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor. / Casal-Dominguez, J. J.; Clark, M.; Traynor, J. R.; Husbands, S. M.; Bailey, Sarah J.

In: Journal of Psychopharmacology, Vol. 27, No. 2, 02.2013, p. 192-202.

Research output: Contribution to journalArticle

@article{09c06e2310264b2ab10d0494310a8cd5,
title = "In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor",
abstract = "Accumulating evidence supports a role for κ−opioid receptor antagonists in the treatment of mood disorders. Standard κ-antagonists have an unusual pharmacodynamic action, with a single injection blocking receptor signaling for several weeks. Here, we have characterized the κ-selective properties of two ligands, 5’-(2-aminomethyl) naltrindole (5’-AMN) and N-((Naltrindol-5-yl) methyl) pentanimidamide (5’-MABN), to identify whether modifications of the naltrindole side chain produces short-acting κ-antagonists. Opioid receptor binding affinity and activity were assessed using [3H]-diprenorphine binding, guanosine-5’-O-(3-[35S]-thio) triphosphate ([35S]-GTPγS) binding and isolated guinea-pig ileum. Pharmacodynamic profiles of 5’-AMN and 5’-MABN (1–10 mg/kg) were investigated using the tail-withdrawal assay and diuresis. Efficacy was also determined in depression- and anxiety-related behavioral paradigms in CD-1 mice. Both 5’-AMN and 5’-MABN had high affinity for κ−receptors (Ki 1.36±0.98 and 0.27±0.08, respectively) and were revealed as potent κ-antagonists (pA2 7.43 and 8.18, respectively) and μ-receptor antagonists (pA2 7.62 and 7.85, respectively) in the ileum. Contrary to our hypothesis, in vivo, 5’-AMN and 5’-MABN displayed long-lasting antagonist effects in mice, reducing the antinociceptive actions of U50,488 (10 mg/kg) at 28 and 21 days post-injection, respectively. Interestingly, while 5’-AMN and 5’-MABN were not κ-selective, both compounds did show significant antidepressant- and anxiolytic-like effects at 7–14 days post-injection in mice.",
author = "Casal-Dominguez, {J. J.} and M. Clark and Traynor, {J. R.} and Husbands, {S. M.} and Bailey, {Sarah J.}",
year = "2013",
month = "2",
doi = "10.1177/0269881112464828",
language = "English",
volume = "27",
pages = "192--202",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "Sage Publications",
number = "2",

}

TY - JOUR

T1 - In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor

AU - Casal-Dominguez, J. J.

AU - Clark, M.

AU - Traynor, J. R.

AU - Husbands, S. M.

AU - Bailey, Sarah J.

PY - 2013/2

Y1 - 2013/2

N2 - Accumulating evidence supports a role for κ−opioid receptor antagonists in the treatment of mood disorders. Standard κ-antagonists have an unusual pharmacodynamic action, with a single injection blocking receptor signaling for several weeks. Here, we have characterized the κ-selective properties of two ligands, 5’-(2-aminomethyl) naltrindole (5’-AMN) and N-((Naltrindol-5-yl) methyl) pentanimidamide (5’-MABN), to identify whether modifications of the naltrindole side chain produces short-acting κ-antagonists. Opioid receptor binding affinity and activity were assessed using [3H]-diprenorphine binding, guanosine-5’-O-(3-[35S]-thio) triphosphate ([35S]-GTPγS) binding and isolated guinea-pig ileum. Pharmacodynamic profiles of 5’-AMN and 5’-MABN (1–10 mg/kg) were investigated using the tail-withdrawal assay and diuresis. Efficacy was also determined in depression- and anxiety-related behavioral paradigms in CD-1 mice. Both 5’-AMN and 5’-MABN had high affinity for κ−receptors (Ki 1.36±0.98 and 0.27±0.08, respectively) and were revealed as potent κ-antagonists (pA2 7.43 and 8.18, respectively) and μ-receptor antagonists (pA2 7.62 and 7.85, respectively) in the ileum. Contrary to our hypothesis, in vivo, 5’-AMN and 5’-MABN displayed long-lasting antagonist effects in mice, reducing the antinociceptive actions of U50,488 (10 mg/kg) at 28 and 21 days post-injection, respectively. Interestingly, while 5’-AMN and 5’-MABN were not κ-selective, both compounds did show significant antidepressant- and anxiolytic-like effects at 7–14 days post-injection in mice.

AB - Accumulating evidence supports a role for κ−opioid receptor antagonists in the treatment of mood disorders. Standard κ-antagonists have an unusual pharmacodynamic action, with a single injection blocking receptor signaling for several weeks. Here, we have characterized the κ-selective properties of two ligands, 5’-(2-aminomethyl) naltrindole (5’-AMN) and N-((Naltrindol-5-yl) methyl) pentanimidamide (5’-MABN), to identify whether modifications of the naltrindole side chain produces short-acting κ-antagonists. Opioid receptor binding affinity and activity were assessed using [3H]-diprenorphine binding, guanosine-5’-O-(3-[35S]-thio) triphosphate ([35S]-GTPγS) binding and isolated guinea-pig ileum. Pharmacodynamic profiles of 5’-AMN and 5’-MABN (1–10 mg/kg) were investigated using the tail-withdrawal assay and diuresis. Efficacy was also determined in depression- and anxiety-related behavioral paradigms in CD-1 mice. Both 5’-AMN and 5’-MABN had high affinity for κ−receptors (Ki 1.36±0.98 and 0.27±0.08, respectively) and were revealed as potent κ-antagonists (pA2 7.43 and 8.18, respectively) and μ-receptor antagonists (pA2 7.62 and 7.85, respectively) in the ileum. Contrary to our hypothesis, in vivo, 5’-AMN and 5’-MABN displayed long-lasting antagonist effects in mice, reducing the antinociceptive actions of U50,488 (10 mg/kg) at 28 and 21 days post-injection, respectively. Interestingly, while 5’-AMN and 5’-MABN were not κ-selective, both compounds did show significant antidepressant- and anxiolytic-like effects at 7–14 days post-injection in mice.

UR - http://www.scopus.com/inward/record.url?scp=84872839981&partnerID=8YFLogxK

UR - http://dx.doi.org/10.1177/0269881112464828

U2 - 10.1177/0269881112464828

DO - 10.1177/0269881112464828

M3 - Article

VL - 27

SP - 192

EP - 202

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 2

ER -